PE20081347A1 - Agomelatina, hidratos, sales, cristales y composiciones de los mismos - Google Patents

Agomelatina, hidratos, sales, cristales y composiciones de los mismos

Info

Publication number
PE20081347A1
PE20081347A1 PE2007001528A PE2007001528A PE20081347A1 PE 20081347 A1 PE20081347 A1 PE 20081347A1 PE 2007001528 A PE2007001528 A PE 2007001528A PE 2007001528 A PE2007001528 A PE 2007001528A PE 20081347 A1 PE20081347 A1 PE 20081347A1
Authority
PE
Peru
Prior art keywords
agomelatin
hydrates
salts
same
crystals
Prior art date
Application number
PE2007001528A
Other languages
English (en)
Spanish (es)
Inventor
Elisabeth Mocaer
Agnes Fabiano
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081347(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20081347A1 publication Critical patent/PE20081347A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Primary Cells (AREA)
  • Connection Of Batteries Or Terminals (AREA)
  • General Preparation And Processing Of Foods (AREA)
PE2007001528A 2006-11-24 2007-11-07 Agomelatina, hidratos, sales, cristales y composiciones de los mismos PE20081347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610296A FR2908995B1 (fr) 2006-11-24 2006-11-24 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis

Publications (1)

Publication Number Publication Date
PE20081347A1 true PE20081347A1 (es) 2008-11-01

Family

ID=38229648

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001528A PE20081347A1 (es) 2006-11-24 2007-11-07 Agomelatina, hidratos, sales, cristales y composiciones de los mismos

Country Status (38)

Country Link
US (1) US20080132577A1 (de)
EP (1) EP1929999B1 (de)
JP (1) JP2008127395A (de)
KR (2) KR20080047299A (de)
CN (1) CN101194901A (de)
AR (1) AR063896A1 (de)
AT (1) ATE501717T1 (de)
AU (1) AU2007234614B2 (de)
BR (1) BRPI0704453A2 (de)
CA (1) CA2610638C (de)
CL (1) CL2007003396A1 (de)
CY (1) CY1111430T1 (de)
DE (1) DE602007013166D1 (de)
DK (1) DK1929999T3 (de)
EA (1) EA013471B1 (de)
ES (1) ES2363252T3 (de)
FR (1) FR2908995B1 (de)
GE (1) GEP20094746B (de)
HR (1) HRP20110370T1 (de)
JO (1) JO2656B1 (de)
MA (1) MA29523B1 (de)
ME (1) ME01959B (de)
MX (1) MX2007014199A (de)
MY (1) MY145139A (de)
NO (1) NO338951B1 (de)
NZ (1) NZ563684A (de)
PE (1) PE20081347A1 (de)
PL (1) PL1929999T3 (de)
PT (1) PT1929999E (de)
RS (1) RS51676B (de)
SA (1) SA07280635B1 (de)
SG (1) SG143203A1 (de)
SI (1) SI1929999T1 (de)
TW (1) TWI370735B (de)
UA (1) UA94042C2 (de)
UY (1) UY30704A1 (de)
WO (1) WO2008071870A2 (de)
ZA (1) ZA200710103B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
ES2645223T3 (es) 2013-06-06 2017-12-04 Zentiva, K.S. Formulaciones de agomelatina que comprenden agomelatina en forma de co-cristales
EP2810647A1 (de) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmazeutische Formulierungen, enthaltend Agomelatin in der Form des Co-Kristalls von Agomelatin mit organischer Säure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1564202A (en) * 1924-05-20 1925-12-08 Christensen Jens Herman Method of producing water-insoluble multicolored screens
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine

Also Published As

Publication number Publication date
KR20080047299A (ko) 2008-05-28
MA29523B1 (fr) 2008-06-02
ME01959B (de) 2011-10-31
ATE501717T1 (de) 2011-04-15
GEP20094746B (en) 2009-07-27
EA013471B1 (ru) 2010-04-30
FR2908995A1 (fr) 2008-05-30
HRP20110370T1 (hr) 2011-06-30
WO2008071870A2 (fr) 2008-06-19
US20080132577A1 (en) 2008-06-05
JP2008127395A (ja) 2008-06-05
UA94042C2 (ru) 2011-04-11
AR063896A1 (es) 2009-02-25
JO2656B1 (en) 2012-06-17
MY145139A (en) 2011-12-30
CA2610638A1 (fr) 2008-05-24
FR2908995B1 (fr) 2009-02-06
EP1929999B1 (de) 2011-03-16
NO20075989L (no) 2008-05-26
AU2007234614A1 (en) 2008-06-12
PT1929999E (pt) 2011-04-08
UY30704A1 (es) 2008-01-02
DE602007013166D1 (de) 2011-04-28
MX2007014199A (es) 2009-02-11
PL1929999T3 (pl) 2011-06-30
NO338951B1 (no) 2016-11-07
KR20110086673A (ko) 2011-07-29
EA200702318A1 (ru) 2008-06-30
CN101194901A (zh) 2008-06-11
DK1929999T3 (da) 2011-06-27
NZ563684A (en) 2009-04-30
SI1929999T1 (sl) 2011-06-30
TW200829237A (en) 2008-07-16
CL2007003396A1 (es) 2008-07-25
CA2610638C (fr) 2013-07-30
SG143203A1 (en) 2008-06-27
CY1111430T1 (el) 2015-08-05
WO2008071870A3 (fr) 2008-08-14
EP1929999A1 (de) 2008-06-11
SA07280635B1 (ar) 2011-10-03
ZA200710103B (en) 2008-11-26
RS51676B (en) 2011-10-31
ES2363252T3 (es) 2011-07-28
TWI370735B (en) 2012-08-21
AU2007234614B2 (en) 2012-06-14
BRPI0704453A2 (pt) 2009-09-08

Similar Documents

Publication Publication Date Title
AR067701A1 (es) Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2
PE20080174A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de la ansiedad generalizada
AR072490A1 (es) 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa
EA201170676A1 (ru) Агонисты рецептора меланокортина
CO6140054A2 (es) Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico
AR082600A1 (es) Polimorfos cristalinos de la sal de besilato de n-(3-(5-fluor-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida, composiciones farmaceuticas que los contienen y uso de los mismos para tratar canceres, enfermedades autoinmunes y oseas, entre otras
ECSP11010878A (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
NI201000209A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
PE20080852A1 (es) Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
PE20080061A1 (es) Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3
GT200600345A (es) Nueva fórmula cristalina iv de la agomelatina. su procedimiento de preparacion y las composiciones farmacéuticas que la contienen
ATE440833T1 (de) Antithrombotische diamide
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
PE20140934A1 (es) Derivados de pirazol
ECSP099565A (es) Compuesto de 2-amino pirimidina
PE20081347A1 (es) Agomelatina, hidratos, sales, cristales y composiciones de los mismos
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
BRPI0910179A2 (pt) composto de amina, composição farmacêutica e uso do composto de amina
BR112012017188A8 (pt) composto agonista de mglu2, sua composição farmacêutica e seu uso
PE20141669A1 (es) Moduladores selectivos del receptor androgeno
DK2076502T3 (da) Substituerede carboxamider som antagonister af gruppe-1 metabotrope receptorer
EA201001882A1 (ru) Гидроксизамещенные тиенопиримидиноны как антагонисты рецептора-i меланинконцентрирующего гормона

Legal Events

Date Code Title Description
FC Refusal